Analyst Report on Nova Pharmaceutical Inc. Claims Opportunity For Strategic Investors|
LAKE ELSINORE, Calif., Feb. 16 /PRNewswire/ -- Nova Pharmaceutical Inc. (OTC Bulletin Board: NOVX) announced today the publication of an independent analysts report released by National Capital Securities (NCS) Research with a recommendation to Buy.
"Nova has completed its development stage and is positioned as a leader in the natural dietary and health supplement industry," says NCS. "The Company's flagship product, NxTrim is a patented, all-natural weight loss aid. According to a retail tracking report provided by the Information Resources Inc., NxTrim held the #1 ranking for diet aids in the California Drug market through 1999," NCS added.
Ralph Mann, President and CEO of Nova, said, "We believe that our company is positioned for rapid growth in the ever growing natural products industry." NCS says, "The Company is able to maintain low overhead, but still is capable of quickly responding to consumer demand."
The analyst report provides details about the nature of Nova's business, its conception, and its products and services. It also demonstrates the Company's financials and investment opinion. "We believe that Nova Pharmaceutical Inc presents a new opportunity for risk-oriented, strategic investors in this developing industry of nutritional supplements," says NCS. NCS adds, "Considering the Company's long term, steady growth outlook, we believe Nova Pharmaceutical Inc is an attractive investment and is targeting a stock price of $10 within the next 18 to 24 months."
About Nova Pharmaceutical Inc.
Nova Pharmaceutical Inc. is a publicly traded company on the OTC Bulletin Board (ticker symbol:NOVX). The company's patented weight loss product, NxTrim, achieved first year sales of $2,000,000, and is currently the number one selling diet aid in the California Drug class of trade according to data provided by Information Resources Inc.
Nova Pharmaceutical Inc is the sole manufacturer, distributor, and marketer of Gold's Gym Nutrition supplements. The company has twenty-three items under the Gold's Gym trademark.
Certain statements in this release are "forward looking" statements as such term is defined in the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.
SOURCE: Nova Pharmaceutical Inc.
CONTACT: Ralph Mann, CEO & President, or Jim Ayres, Vice President & Secretary, both of Nova Pharmaceutical Inc., 888-495-NOVA (6682), email@example.com; or Joe Stapley of Travis Morgan Securities, 949-261-2906, for Nova Pharmaceutical Inc.